Insights - Essa Pharma (EPIX) is entering a second-gen drug, with a novel mechanism of action, into clinic for advanced prostate cancer The first-gen drug showed to … Continue Reading
PremiumInsights - Last Friday, San Raffaele Hospital in Milan, Italy, published data using La Jolla’s Giapreza in compassionate use. The study demonstrated that Giapreza was able to improve oxygenation … Continue Reading
PremiumInsights - Affimed & Genentech/Roche released their preclinical abstract for an anti-BCMA/CD16a bi-specific antibody in multiple myeloma today for the American Association of Cancer Research (AACR) conference. This affiliation confirms the … Continue Reading
PremiumInsights - Aimmune announced their first quarter of Palforzia launch yesterday and it was greatly impacted by Covid. Sales for the quarter were $600K, about half of the Street’s projection … Continue Reading
PremiumInsights - La Jolla (LJPC) released Q1 numbers today. Although we were expecting a larger jump, as a result of the COVID situation and increase in demand … Continue Reading
PremiumInsights - Stemline (STML), one of our holdings, was acquired this morning for $11.50 in cash + $1 in form of a Contingent Value Right (CVR). The CVR will … Continue Reading
PremiumInsights - Yesterday Fennec announced the pricing of their public offering. The company raised $30M by issuing 4.8M shares @ $6.25/share. About a 13% discount to market price. We … Continue Reading
Premium
